Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 22 Jul 2021
Astra blitz: Scott Morrison says get the COVID-19 vaccine now
22 July 2021 - Scott Morrison has apologised for the nation’s behind schedule vaccine program and told young people the ...
Posted by Michael Wonder on 22 Jul 2021
NHS England unveils new Innovative Medicine Fund
21 July 2021 - NHS England has unveiled its new Innovative Medicines Fund, to ensure patients have early access to ...
Posted by Michael Wonder on 22 Jul 2021
ICER releases draft evidence report on therapies for myasthenia gravis
22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 22 Jul 2021
Roche is discussing Alzheimer’s drug with FDA following regulators controversial approval of Biogen’s Aduhelm, CEO says
22 July 2021 - Roche is discussing its potential Alzheimer’s treatment with the U.S. FDA, CEO Severin Schwan said Thursday, ...
Posted by Michael Wonder on 22 Jul 2021
FDA approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination for patients with certain types of advanced endometrial carcinoma
22 July 2021 - Immunotherapy and tyrosine kinase inhibitor combination approved for the treatment of patients with advanced endometrial carcinoma that ...
Posted by Michael Wonder on 22 Jul 2021
Bayer’s new symptomatic chronic heart failure treatment Verquvo (vericiguat) approved in EU
21 July 2021 - Approved for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring ...
Posted by Michael Wonder on 22 Jul 2021
Patients with rare bile duct cancer set to benefit from life extending treatment
22 July 2021 - Some people who have a rare form of bile duct cancer are set to benefit from life-extending ...
Posted by Michael Wonder on 22 Jul 2021
bluebird bio receives EC approval for Skysona (elivaldogene autotemcel, Lenti-D) gene therapy for patients less than 18 years of age with early cerebral adrenoleukodystrophy without matched sibling donor
21 July 2021 - Skysona is the first and only gene therapy approved in the European Union to treat early CALD. ...
Posted by Michael Wonder on 22 Jul 2021
RareStone announces submission of new drug application of Wakix (pitolisant) for narcolepsy with and without cataplexy in China
21 July 2021 - Application is supported by data used in the Wakix EMA and the U.S. FDA approvals. ...
Posted by Michael Wonder on 22 Jul 2021
COVID-19 vaccine weekly safety report (22 July 2021)
22 July 2021 - Over the last week, four additional cases of blood clots with low blood platelets have been assessed ...
Posted by Michael Wonder on 21 Jul 2021
We’re seeing what happens when the FDA loses credibility
21 July 2021 - It’s not just politicians who are worried about the decision to approve a new Alzheimer’s drug. ...
Posted by Michael Wonder on 21 Jul 2021
Vaccine mandates more likely once FDA grants full approvals, health experts say
20 July 2021 - The regulatory sign-off would remove a significant legal and public relations barrier to requirements, former government officials ...
Posted by Michael Wonder on 21 Jul 2021
PrEP, the HIV prevention pill, must now be totally free under almost all insurance plans
21 July 2021 - Insurers have been advised that they shouldn’t be charging for Truvada and Descovy as HIV prevention and ...
Posted by Michael Wonder on 21 Jul 2021
Fit for purpose real world data assessments in oncology: a call for cross stakeholder collaboration
21 July 2021 - Real world evidence remains a promising frontier in evidence generation to support improved health related patient outcomes. ...
Posted by Michael Wonder on 21 Jul 2021
Recently approved Alzheimer drug raises questions that might never be answered
21 July 2021 - The FDA’s approval June 7 of the drug aducanumab was notable for a number of reasons. ...